Abstract
In the clinical scenario of a persistently elevated PSA with a prior negative biopsy, the aforementioned studies clearly demonstrate the additional predictive abilities of numerous biomarkers that add additional value above and beyond PSA combined with available clinical metrics. Future studies should focus specifically on the detection of high-grade prostate cancer, cost-effectiveness of widescale implementation, and incorporation of biomarkers into multinomial predictive tools or calculators. Additionally, although our patient was specifically interested in biomarkers, the emerging imaging platforms (e.g., multiparametric MRI) will need to be integrated within the biomarker domain with perhaps a low-cost biomarker serving as a trigger for advanced imaging as has been suggested by others. At this point for our patient, in alignment with established guidelines, we would recommend consideration of one of the biomarkers with particular attention to the high NPV for detection of prostate cancer at the next biopsy.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463–6.
Thompson IM, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98:529–34.
Roobol MJ, et al. A risk-based strategy improves prostate-specific antigen–driven detection of prostate cancer. Eur Urol. 2010;57:79–85.
ElShafei A, et al. More favorable pathological outcomes in men with low risk prostate cancer diagnosed on repeat versus initial Transrectal ultrasound guided prostate biopsy. J Urol. 2016;195:1767–72.
Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am. 1997;24:333–8.
Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990;194:755–63.
Christensson A, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100–5.
Catalona WJ, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542–7.
Partin AW, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis. 1998;1:197–203.
Ankerst DP, et al. Serial percent-free PSA in combination with PSA for population-based early detection of prostate cancer. J Urol. 2016;196:355–60.
Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol. 1997;158:2162–7.
Catalona WJ, et al. A multi-center study of [−2]pro-prostate-specific antigen (PSA) in Combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range. J Urol. 2011;185:1650–5.
Loeb S, et al. The prostate Health Index selectively identifies clinically significant prostate cancer. J Urol. 2015;193:1163–9.
Loeb S, et al. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 2017;120:61–8.
Lazzeri M, et al. Serum Index test %[−2]proPSA and prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol. 2012;188:1137–43.
Boegemann M, et al. The percentage of prostate-specific antigen (PSA) isoform [−2]proPSA and the prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. BJU Int. 2016;117:72–9.
Vickers AJ, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in Göteborg, Sweden. BMC Med. 2008;6:19.
Vickers A, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-Kallikrein panel: an independent replication. J Clin Oncol. 2010;28:2493–8.
Parekh DJ, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464–70.
Bryant RJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015;107. https://doi.org/10.1093/jnci/djv095.
Gupta A, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European randomized study of prostate cancer screening in Rotterdam, Netherlands. Br J Cancer. 2010;103:708–14.
Nordström T, et al. Comparison between the four-kallikrein panel and prostate Health Index (PHI) for predicting prostate cancer. Eur Urol. 2015;68:139–46.
Bussemakers MJG, et al. DD3: a new prostate-specific Gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–9.
Deras IL, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–92.
Marks LS, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532–5.
Haese A, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081–8.
Aubin SMJ, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the Dutasteride REDUCE trial. J Urol. 2010;184:1947–52.
Gittelman MC, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013;190:64–9.
Wei JT, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014;32:4066–72.
Van Neste L, et al. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72:1248–61.
Stewart GD, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013;189:1110–6.
Partin AW, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192:1081–7.
Van Neste L, et al. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate. 2016;76:1078–87.
European Association of Urology. Prostate Cancer. Uroweb. 2014. http://uroweb.org/guideline/prostate-cancer/#5. Accessed 11 Oct 2017.
Carter HB, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419–26.
Leyten GHJM, et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci. 2013;14:11347–55.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Kearns, J.T., Lin, D.W. (2018). Utilizing Biomarkers in Patients with Prior Negative Prostate Biopsy. In: Chang, S., Cookson, M. (eds) Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-78646-9_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-78646-9_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78645-2
Online ISBN: 978-3-319-78646-9
eBook Packages: MedicineMedicine (R0)